Cot modulators and methods of use thereof
The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
1. A compound having the formula:
or a pharmaceutically acceptable salt thereof.
2. A composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
3. A method of treating a disease or condition selected from diversion colitis, ischemic colitis, infectious colitis, chemical colitis, microscopic colitis, atypical colitis, pseudomembranous colitis, fulminant colitis, autistic enterocolitis, indeterminate colitis, Behget's disease, gastroduodenal CD, jejunoileitis, ileitis, ileocolitis, Crohn's (granulomatous) colitis, irritable bowel syndrome, mucositis, radiation induced enteritis, short bowel syndrome, celiac disease, stomach ulcers, diverticulitis, pouchitis, proctitis, chronic diarrhea, Crohn's disease, and ulcerative colitis, in a human patient in need thereof, comprising administering to the patient an effective amount of the composition of claim 2 .
4. A method of treating inflammatory bowel disease in a human patient in need thereof, comprising administering to the patient an effective amount of the composition of claim 2 .